Kiniksa Pharmaceuticals Internation (KNSA) stock
NASDAQ
As of the Nov 17, 2026 close (U.S. Eastern)
- Market cap
- $7.47B
- As of Nov 17, 2026
- P/E
- 68.57x
- Trailing twelve months
- P/B
- 10.53x
- Latest reported equity
- P/S
- 7.90x
- Trailing twelve months
- ROE
- 15.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
- Market cap
- $7.47B
- As of Nov 17, 2026
- P/E
- 68.57x
- Trailing twelve months
- P/B
- 10.53x
- Latest reported equity
- P/S
- 7.90x
- Trailing twelve months
- ROE
- 15.4%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 17, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
68.57x
P/B
10.53x
P/S
7.90x
Earnings and dividend metrics▾
Earnings
EPS
—
Earnings per share
BPS
—
Book value per share
ROE
15.4%
Return on equity
- ROE — how much the company earned on shareholder equity over a year: 15.4%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 58.0% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $181M+58.0%
$112M
Jul–Sep '24
$181M
Jul–Sep '25
$286M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 27, 2026.
- Earnings per share increased 143.5% from the same quarter a year earlier.
- Revenue increased 58.0% from the same quarter a year earlier.
- Operating income increased 125.0% from the same quarter a year earlier.
- Net income increased 161.1% from the same quarter a year earlier.
Filed Oct 27, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Paolini John F.CHIEF MEDICAL OFFICER · Nov 13, 2026Option exercise44,126 shares · $488KAvg. price $11.069
Show 5 price lots
- 29,670 shares × $10.36$307K
- 4,994 shares × $11.1$55K
- 3,723 shares × $11.97$45K
- 3,144 shares × $12.97$41K
- 2,595 shares × $15.52$40K
- Megna Michael RCHIEF ACCOUNTING OFFICER · Nov 9, 2026Open-market sale11,280 shares · $1.1MAvg. price $98.5412,697 shares held after
- Megna Michael RCHIEF ACCOUNTING OFFICER · Nov 9, 2026Option exercise11,280 shares · $200KAvg. price $17.7623,977 shares held after
- Patel Sanj KCHAIRMAN & CEO · Nov 4, 2026Open-market sale151,300 shares · $14.3MAvg. price $94.7143
Show 5 price lots
- 81,742 shares × $94.2$7.7M
- 29,845 shares × $95.48$2.8M
- 26,918 shares × $96.05$2.6M
- 11,335 shares × $93.54$1.1M
- 1,460 shares × $92.35$135K
- Patel Sanj KCHAIRMAN & CEO · Nov 4, 2026Option exercise145,763 shares · $2.6MAvg. price $17.92925,800 shares held after
- Patel Sanj KCHAIRMAN & CEO · Nov 3, 2026Open-market sale220,170 shares · $20.5MAvg. price $93.2709
Show 4 price lots
- 145,708 shares × $93.53$13.6M
- 68,664 shares × $92.7$6.4M
- 4,584 shares × $94.25$432K
- 1,214 shares × $90.77$110K
- Patel Sanj KCHAIRMAN & CEO · Nov 3, 2026Option exercise130,326 shares · $1.5MAvg. price $11.7062
Show 2 price lots
- 89,089 shares × $8.83$787K
- 41,237 shares × $17.92$739K
- Patel Sanj KCHAIRMAN & CEO · Nov 2, 2026Open-market sale89,433 shares · $8.2MAvg. price $91.8575
Show 4 price lots
- 38,364 shares × $91.03$3.5M
- 26,781 shares × $93.06$2.5M
- 24,188 shares × $91.83$2.2M
- 100 shares × $93.97$9K
- Paolini John F.CHIEF MEDICAL OFFICER · Nov 2, 2026Open-market sale18,413 shares · $1.7MAvg. price $93.3944
Show 3 price lots
- 16,810 shares × $93.42$1.6M
- 899 shares × $92.37$83K
- 704 shares × $94.09$66K
- Ragosa MarkCHIEF FINANCIAL OFFICER · Nov 2, 2026Open-market sale36,783 shares · $3.4MAvg. price $92.1615
Show 4 price lots
- 14,027 shares × $91.4$1.3M
- 12,034 shares × $93.13$1.1M
- 10,502 shares × $92.03$966K
- 220 shares × $94.01$21K
- Moat RossCHIEF OPERATING OFFICER · Nov 2, 2026Open-market sale27,977 shares · $2.6MAvg. price $92.3635
Show 4 price lots
- 11,642 shares × $93.15$1.1M
- 8,932 shares × $92.05$822K
- 6,681 shares × $91.23$610K
- 722 shares × $94.05$68K
- Patel Sanj KCHAIRMAN & CEO · Nov 2, 2026Option exercise53,381 shares · $471KAvg. price $8.83959,314 shares held after
- Moat RossCHIEF OPERATING OFFICER · Nov 2, 2026Option exercise21,714 shares · $438KAvg. price $20.1619
Show 2 price lots
- 12,302 shares × $21.77$268K
- 9,412 shares × $18.06$170K
- Paolini John F.CHIEF MEDICAL OFFICER · Nov 2, 2026Option exercise18,413 shares · $414KAvg. price $22.4809
Show 2 price lots
- 11,958 shares × $17.92$214K
- 6,455 shares × $30.93$200K
- Ragosa MarkCHIEF FINANCIAL OFFICER · Nov 2, 2026Option exercise9,636 shares · $171KAvg. price $17.7657,637 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Kiniksa Pharmaceuticals Internation (KNSA) stock information
NASDAQ
Kiniksa Pharmaceuticals Internation (KNSA) is listed on NASDAQ. Its market capitalization is about $7.5B. On trailing-twelve-month earnings the P/E ratio is 68.57, and the P/B ratio is 10.53. Return on equity is 15.4%. These figures are computed in-house from official filings and are reference information only.
Kiniksa Pharmaceuticals Internation — frequently asked questions
- What is the P/E ratio of Kiniksa Pharmaceuticals Internation (KNSA)?
- On a trailing-twelve-month basis, KNSA trades at a P/E ratio of 68.57. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Kiniksa Pharmaceuticals Internation?
- KNSA has a market capitalization of about $7.5B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.